BioSpace News Archive

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona’s investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.

Armata Pharmaceuticals, Inc. today announced that the Company will present and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference taking place July 13-14, 2021.

UVision360, Inc., an innovative medical device company, announces that the U.S. Food and Drug Administration has approved the patented LUMINELLE 360° Bx Sheath which expands the capability of the LUMINELLE® DTx System.

Purisys LLC, a leading supplier of active pharmaceutical ingredients, contract development and manufacturing services, and pharmaceutical reference materials, announced that it has obtained two additional global ISO certifications: ISO 17025 and ISO 17034.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced a clinical supply agreement with Regeneron for Libtayo® (cemiplimab).

Adagene Inc. today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced the Health Canada approval and availability of Vyxeos® (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Braxia Scientific Corp. is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021.